Tag Archive for: kidney cancer

Posts

Article of the Week: Early surgical outcomes and oncological results of RAPN

Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full article, which is freely available to all readers for at least 30 days from the time of this post.

In addition to the article itself, there is an accompanying editorial written by a prominent member of the urological community. This blog is intended to provoke comment and discussion and we invite you to use the comment tools at the bottom of each post to join the conversation.

If you only have time to read one article this week, it should be this one.

Early surgical outcomes and oncological results of robot-assisted partial nephrectomy: a multicentre study

 

Rajan Veeratterapillay*, Sanjai K. Addla, Clare Jelley, John Bailie*, David Rix*,Steve Bromage, Neil Oakley, Robin Weston§ and Naeem A. Soomro*

 

*Department of Urology, Freeman Hospital, Newcastle Upon Tyne, Department of Urology, Bradford Teaching Hospitals NHS Foundation Trust, Bradford, Department of Urology, Stepping Hill Hospital, Stockport, and §Department of Urology, Royal Liverpool University Hospital, Liverpool, UK

 

Abstract

Objective

To describe a multicentre experience of robot-assisted partial nephrectomy (RAPN) in northern England, with focus on early surgical outcomes and oncological results.

Patients and Methods

All consecutive patients undergoing RAPN at four tertiary referral centres in northern England in the period 2012–2015 were included for analysis. RAPN was performed via a transperitoneal approach using a standardized technique. Prospective data collection was performed to capture preoperative characteristics (including R.E.N.A.L. nephrometry score), and peri-operative and postoperative data, including renal function. Correlations between warm ischaemia time (WIT), positive surgical margin (PSM) rate, complication rates, R.E.N.A.L. nephrometry scores and learning curve were assessed using univariate and multivariate analyses.

Results

A total of 250 patients (mean age 58.1 ± 13 years, mean ± sd body mass index 27.3 ± 7 kg/m2) were included, with a median (range) follow-up of 12 (3–36) months. The mean ± sd tumour size was 30.6 ± 10 mm, mean R.E.N.A.L. nephrometry score was 6.1 ± 2 and 55% of tumours were left-sided. Mean ± sd operating console time was 141 ± 38 min, WIT 16.7 ± 8 min and estimated blood loss 205 ± 145 mL. There were five conversions (2%) to open/radical nephrectomy. The overall complication rate was 16.4% (Clavien I, 1.6%; Clavien II, 8.8%; Clavien III, 6%; Clavien IV/V; 0%). Pathologically, 82.4% of tumours were malignant and the overall PSM rate was 7.3%. The mean ± sd preoperative and immediate postoperative estimated glomerular filtration rates were 92.8 ± 27 and 80.8 ± 27 mL/min/1.73 m2, respectively (P = 0.001). In all, 66% of patients remained in the same chronic kidney disease category postoperatively, and none of the patients required dialysis during the study period. ‘Trifecta’ (defined as WIT < 25 min, negative surgical margin status and no peri-operative complications) was achieved in 68.4% of patients overall, but improved with surgeon experience. PSM status and long WIT were significantly associated with early learning curve.

Conclusion

This is the largest multicentre RAPN study in the UK. Initial results show that RAPN is safe and can be performed with minimal morbidity. Early oncological outcomes and renal function preservation data are encouraging.

Editorial: From Novick to the NHS – the evolution of minimally-invasive NSS

The publication in this issue of the BJUI by Veeratterapillay et al. [1] of a UK multicentre study in a community setting marks a watershed in the availability and quality of minimally invasive nephron-sparing surgery (NSS) for renal cancer. Such a turning point was predicted almost 17 years ago by Novick [2] when he wrote, ‘minimally invasive modalities of tumour resection or destruction should be reserved for highly select patients and awaits improvements in technology, standardization of technique and long-term outcomes data before they may be completely integrated options’. It appears now that robot-assisted surgery provides such a platform. The present study [1] describes the outcomes of patients treated with robot-assisted partial nephrectomy (RAPN) at four centres in Northern England, and shows very good outcomes within their first 250 cases.

The benefits of NSS have been well described. Indeed, excellent outcomes for PN were described over 20 years ago in carefully selected cases, with benefits including reduced incidence of renal insufficiency compared to radical nephrectomy, which until that time had been viewed as the ‘gold-standard’ for patients with RCC [3]. However, the popularity of PN for small renal masses appeared to decline with the advent of laparoscopy. It became apparent that a minimally invasive approach to radical nephrectomy had the advantage of improved recovery, reduced blood loss with equal cancer control to open nephrectomy [4]. Notwithstanding absolute and relative indications for PN, given the choice between an open PN and a laparoscopic radical nephrectomy, the balance for patients with an elective indication for PN was tipped in favour of a minimally invasive yet radical approach [5]. Techniques for PN were in their infancy, and even in the leading high-volume centres outcomes, including warm ischaemia time (WIT) and positive surgical margin (PSM) rate, failed to match those of open surgery [6].

Fast forward to 2017 with the increasing use of robot-assisted urological surgery carrying the advantages of three-dimensional vision, wristed movement and integrated real-time intraoperative imaging, especially beneficial for procedures such as PN where quick and accurate suturing are essential for a successful outcome. Veeratterapillay et al. [1] present a series of 250 patients from centres in the UK, in which each performs <50 RAPN procedures/year, yet the authors present favourable outcomes overall, with a PSM rate of 7.3%, major complications in 6% and trifecta in 68.4%. An impressive learning curve is seen with improving outcomes over the series, such that in the final 50 cases a trifecta (WIT <25 min, negative surgical margin and absence of complications) was achieved in 82% of cases, with a PSM rate of 2% despite increasing complex nephrometry scores, which compares favourably with larger series from internationally renowned centres [6].

So then, with the results of the present study [1], can we say that Novick’s requirements have been met, and that minimally invasive NSS is now a ‘completely integrated option’? Certainly, with the widespread adoption of robot-assisted surgery, high-quality outcomes are within the grasp of centres other than elite academic institutions. As techniques develop and experience grows robot-assisted surgery can be increasingly offered, even for resection of more complex tumours.

To ensure that minimally invasive NSS is delivered to the highest standards, it will be necessary for providers to ensure both quality assurance and quality control in their processes. The learning curve needs to be minimised with structured teaching and mentoring, and the use of adjuncts such as intraoperative ultrasonography or fluorescence should be a routine part of care.

Centres offering this technique should be mindful of the well documented volume–outcome relationship that appears to be ubiquitous among complex surgical procedures. If centres are performing less than an optimum number of cases, they may consider affiliating themselves with other such centres in networks and forming a joint clinical governance programme, as has been described for robot-assisted radical prostatectomy and which has shown demonstrable improvements in outcomes.

Finally, auditing and reporting of outcomes remains the cornerstone of quality assurance as shown by the introduction of the BAUS complex surgery audit, which is intended to drive standards of care forward. Publications such as that of Veeratterapillay et al. [1] greatly assist in documenting the progress of new techniques and emerging technologies. Increasingly, patients expect transparency from healthcare providers, and with the necessary support processes in place, such initiatives, and the data that they produce will help to further improve the delivery of complex surgery to patients from all areas of our practice.

Benjamin W. Lamb* and Daniel A. Moon*

 

*Division of Cance r Surgery, Peter MacCallum Cancer Centre, Epworth Healthcare, and Department of Surgery, Central Clinical School, Monash University, Melbourne, Vic., Australia

 

References

 

1 Veeratterapillay R, Addla SK, Jelley C et al. Early surgical outcomes and oncological results of robot-assisted partial nephrectomy: a multicentre study. BJU Int 2017; 120: 5505

 

2 Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. J Urol 2001; 166: 618

 

3 Polascik TJ, Pound CR, Meng MV, Partin AW, Marshall FF. Partial nephrectomy: technique, complications and pathological ndings. J Urol 1995; 154: 131218

 

4 Gill IS, Meraney AM, Schweizer DK et al. Laparoscopic radical nephrectomy in 100 patients. Cancer 2001; 92: 184355

 

5 Novick AC. Laparoscopic and partial nephrectomy. Clin Cancer Res 2004; 10: 6322S7S

 

 

Article of the Week: When to Perform Preoperative Chest CT for RCC Staging

Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full article, which is freely available to all readers for at least 30 days from the time of this post.

In addition to the article itself, there is an accompanying editorial written by a prominent member of the urological community. This blog is intended to provoke comment and discussion and we invite you to use the comment tools at the bottom of each post to join the conversation.

If you only have time to read one article this week, it should be this one.

When to perform preoperative chest computed tomography for renal cancer staging

Alessandro Larcher*, Paolo DellOglio*, Nicola Fossati*, Alessandro Nini*Fabio Muttin*, Nazareno Suardi*, Francesco De Cobelli, Andrea Salonia*Alberto Briganti*, Xu Zhang§, Francesco Montorsi*, Roberto Bertini*† and Umberto Capitanio*

 

*Division of Experimental Oncology, URI – Urological Research Institute, Unit of Urology, Vita-Salute San Raffaele University, Unit of Radiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, Italy, and § Clinical Division of Surgery, Department of Urology, Chinese PLA General Hospital, Beijing, China

 

Abstract

Objectives

To provide objective criteria for preoperative staging chest computed tomography (CT) in patients diagnosed with renal cell carcinoma (RCC) because, in the absence of established indications, the decision for preoperative chest CT remains subjective.

Patients and Methods

A total of 1 946 patients undergoing surgical treatment of RCC, whose data were collected in a prospective institutional database, were assessed. The outcome of the study was presence of pulmonary metastases at staging chest CT. A multivariable logistic regression model predicting positive chest CT was fitted. Predictors consisted of preoperative clinical tumour (cT) and nodal (cN) stage, presence of systemic symptoms and platelet count (PLT)/haemoglobin (Hb) ratio.

Results

The rate of positive chest CT was 6% (n = 119). At multivariable logistic regression, ≥cT1b, cN1, systemic symptoms and Hb/PLT ratio were all associated with higher risk of positive chest CT (all P < 0.001). After 2000-sample bootstrap validation, the concordance index was found to be 0.88. At decision-curve analysis, the net benefit of the proposed strategy was superior to the select-all and select-none strategies. Accordingly, if chest CT had been performed when the risk of a positive result was >1%, a negative chest CT would have been spared in 37% of the population and a positive chest CT would have been missed in 0.2% of the population only.

Conclusions

The proposed strategy estimates the risk of positive chest CT at RCC staging with optimum accuracy and the results were statistically and clinically relevant. The findings of the present study support a recommendation for chest CT in patients with ≥cT1b, cN1, systemic symptoms or anaemia and thrombocythemia. Conversely, in patients with cT1a, cN0 without systemic symptoms, anaemia and thrombocythemia, chest CT could be omitted.

Editorial: Do all patients with renal cell carcinoma need a chest computed tomography?

While all patients with RCC need chest imaging for staging evaluation, the answer to the question in the title is ‘No’, and, in fact, many patients would be adequately staged with a chest X-ray, albeit with reduced accuracy. Evidence to support this assertion is provided by Larcher et al. [1] in this issue of BJUI, who retrospectively evaluated 1946 patients with a solitary and sporadic RCC mass. While excluding patients who did not have surgery and those with visceral metastases seen on abdominal imaging, the authors observed pulmonary metastases in 6% (119 patients) of their population. In a multivariable analysis, features associated with a positive chest CT included cT1b+, cN1, systemic symptoms, anaemia, and thrombocytosis. Incorporating these features into a predictive model, the authors report a robust concordance index of 0.88, with the effect of each feature demonstrated in a nomogram. Further, the authors report that if a chest CT is only performed when the risk of a positive result is >1%, 37% of their population could have been spared a chest CT while missing a positive result in only 0.2% (four patients). Patient factors that predict for a <1% risk of a positive chest CT essentially include those with cT1aN0 RCC without systemic symptoms, anaemia, or thrombocytosis. Thus, the authors conclude that in these low-risk patients, a chest CT can be omitted, while any patient that is cT1b+, cN1, or with systemic symptoms, anaemia, or thrombocytosis warrants a dedicated chest CT at diagnosis.

The finding that patients with RCC with smaller tumours (cT1a or ≤4 cm) were unlikely to harbour pulmonary metastases is consistent with prior literature. Observations from the Memorial Sloan-Kettering Cancer Center (MSKCC) [2], and subsequently validated by our group at Mayo Clinic [3], suggested that among surgically treated patients with RCC, risk of M1 disease (at any location) at diagnosis was non-existent for tumours of <2 cm, was <1% for tumours of 2–3 cm, and was only 1–2% for tumours of 3-4 cm in size. Given that it is rare for patients with small renal masses to endorse systemic symptoms or have paraneoplastic symptoms related to the tumour, these prior observations suggest a lack of utility for chest CT for patients with small renal masses supporting the findings from Larcher et al. [1].

In patients with RCC with synchronous metastases, lung is the most common site of spread and guidelines uniformly recommend chest imaging at diagnosis. However, a ‘select-all’ strategy for chest CT in patients with renal masses leads to unnecessary findings in those with a benign primary tumour, increased use of healthcare resources, and relatively frequent findings of indeterminate lesions. In fact, contemporary observations from the MSKCC found that about half of patients with RCC undergoing surgery had indeterminate pulmonary nodules on chest CT that required either additional evaluation or subsequent chest CT to document stability [4]. Further, the presence of indeterminate pulmonary nodules was not associated with distant metastases or death from RCC after surgery unless they were >1 cm, which only represented a small portion (4%) of the entire cohort [4]. Thus, the analysis from Larcher et al. [1] in this issue of BJUI has meaningful clinical relevance; that is, patients with cT1aN0 RCC without symptoms or laboratory abnormalities do not require a chest CT for screening of their lungs.

R. Houston Thompson
Department of Urology, Mayo Clinic, Rochester, MN, USA

 

 

References

 

1 Larcher A, DellOglio P, Fossati N et al. When to perform preoperative chest computed tomography for renal cancer staging. BJU Int 2017; 120: 4906

 

2 Thompson RH, Hill JR, Babayev Y et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol 2009; 182: 415

 

3 Umbreit EC, Shimko MS, Childs MA et al. Metastatic potential of renal mass according to original tumour size at presentation. BJU Int 2011; 109: 1904

 

 

Immunotherapy in urological malignancies: can you take your knowledge to the next level?

bju13648-fig-0001In this month’s issue of the BJUI, we highlight the evolving era of immunotherapy in solid tumour therapy. As urological surgeons, we spend a large portion of our time working with anatomy, instruments, and robots – things we can see, touch, and control. Immunotherapy is a different conversation – cartoon pathways, process blockades, molecular expression levels, combination therapies, and treatment resistance. Curing a patient with a successful operation is a major draw to our field, but we know our limitations when faced with lethal variant prostate cancer, and high-grade/high-stage bladder and kidney cancers in particular. Systemic therapies have been around for decades and are part of our guidelines – so why all the excitement over immunotherapy?

Our highlighted articles are a review from Mataraza and Gotwals [1] and a comment from Elhage et al. [2]. I urge you to start with the review article [1] and give it a full line-by-line read. You may need to pull out pen and paper, and practice spelling and pronouncing a number of new compounds. They may sound as awkward as abiraterone did the first time you heard of it years ago but will eventually become familiar and attached to yet another catchy trade name from pharma. Here is a quick list/homework assignment: ipilimumab, nivolumab, pembrolizumab, pidilizumab, atezolizumab. Another 20 or more are in development. Challenge yourself to write out their pathways, and you may re-learn a thing or two about familiar agents like sipuleucel-T, interferon α, and interleukin 2.

A major theme in both articles is the experience with immunotherapy in advanced melanoma. The enticing message is that a cohort of patients with metastatic melanoma treated with ipilimumab survived 3 years and the Kaplan–Meier curves plateau out to 10 years. This observation sparks different possible futures such as immune ‘memory’, durable response, and ultimately the word we like to use in surgery – cure.

The picture in urological cancers is not entirely as rosy as the melanoma Kaplan–Meier curve. Multiple trials are highlighted by our review with familiar themes of single agent trials, combination immunotherapies, and combined immunotherapy plus anti-angiogenesis agents. Many trials enrol heavily pre-treated populations with limited remaining options. Many endpoints still observe responses followed by resistance patterns. An important theme to follow is the coupling of biomarkers that link expression to treatment response (i.e. predictive vs prognostic), and the USA Food and Drug Administration (FDA) has approved such a biomarker for nivolumab response. However, even this story line is perplexing, as drug response is not always linked to the marker, and immune cell expression may be ‘inducible and dynamic’ [1].

Last step – re-read the review and comment articles and see if you can write down some key agenda items for future immunotherapy. How are checkpoint inhibitors different from vaccines? How do we generate a durable immune response? What is the ‘abscopal effect’? What are three major areas of research and development in immunotherapy?

If you can spend the time on these articles and ponder these challenging questions, you will move up to the next level of understanding and enjoy a greater appreciation of the next abstract you hear at a major meeting. In closing, I am reminded of the oft-repeated words from the hit television show Game of Thrones (based on the novels of George R.R. Martin) from the House Stark: ‘Winter is Coming’. In urological oncology, ‘Immunotherapy is Coming’, so be prepared!

 

John W. Davis

BJUI Associate Editor Urological Oncology

 

References

1 Mataraza JM, Gotwals P. Recent advances in immuno-oncology and its application to urological cancers. BJU Int 2016; 118: 50614

 

2 Elhage O, Galustian C , Dasgupta P. Immune checkpoint blockade treatment for urological cancers? BJU Int 2016; 118: 498505

 

What gets Indy Gill REALLY excited?

Dr Indy Gill, as everyone knows, has always been a pioneer of minimally invasive surgery, and has continued to push the boundaries of this over the past 20 years. Some of this progress has been seriously exciting, both for us mere mortals who have visited his operating room or viewed his live surgery, and also for Dr Gill as he has continued to reinvent what is possible.   Tackling a Level II/III caval thrombus using robotic surgery, exploring nephron-sparing surgery with anatomically extreme tumours, and now zero ischaemia – all of this progress has been very thrilling indeed.

But last week, I realised that there is something that is capable of getting the great Dr Gill REALLY excited, and I thought I would share that with you.

It started after Indy accepted an invitation from myself and my colleague, Daniel Moon, to join our international faculty at the National Bladder and Kidney Cancer Symposium which we convene here in Melbourne. Our faculty already included Dr Mike Stifleman (NYU), Dr Colin Dinney (MD Anderson), Dr Simon Horenblas (National Cancer Institute, The Netherlands), Dr Nick James (University of Birmingham), and Dr Maha Hussein (University of Michigan), as well as an excellent faculty from around Australia and New Zealand. This symposium is convened at the world famous Melbourne Cricket Ground (MCG), one of the world’s greatest sporting arenas, and one of the most famous cricket grounds in the world. It recently broke the world record for attendance at an international test cricket match when over 91,000 people attended the Australia versus England “Ashes” match on Boxing Day.

I was aware that Indy receives about 1000 emails per day and we wanted to catch his eye as we planned the program. I therefore emailed him with the subject heading, “Opening the batting at the MCG?”, in the certain knowledge that as a self-confessed “cricket tragic”, he might just respond! And here is his response:

  

Apologies to those (me included) who do not understand “cricket-speak”! However one can tell that Indy, like everyone else I know from the sub-continent, is a big cricket fan. The stage was therefore set: our Symposium would benefit from Indy presenting a spectacular overview of advances in nephron-sparing surgery with the wonderful backdrop of one of the world’s greatest sporting arenas and a mecca for cricket lovers.

What we did not know was that by chance, one of the greatest cricketers of all time, legendary leg-spin bowler Shane Warne, was hosting a private charity cricket match in aid of The Shane Warne Foundation on the hallowed turf during our Symposium. As soon as we realised, we started plotting to see if we could arrange for the Urology Legend to meet the Cricket Legend. A few phone calls later and it had been agreed- “Warney” would meet Indy at 08:30 the next morning.

Put simply, I have never seen anybody so excited in my entire life. I don’t think Indy slept very much as he looked forward with child-like amazement to his encounter with one of the greatest cricket players of all time. He paced up and down somewhat nervously (I would say considerably more nervous than he would be before performing one of his live surgery spectaculars to a gigantic audience), as we waited for our escort to bring us to the home team changing room at the MCG. He seemed somewhat breathless, he was speaking terribly quickly, his eyes scanning nystagmus-like as he looked like someone having a supraventricular tachycardia.

Meanwhile in the auditorium upstairs, Indy’s colleague Dr Mihir Desai, another cricket tragic, was broadcasting a live robotic cystectomy from the University of Southern California to our auditorium. When we explained that Indy was a little delayed as he was meeting Shane Warne downstairs, this was met with an audible sigh along with some muttering from Dr Desai’s robot console as he clearly would much prefer to have been in Melbourne than in California at that particular moment. “Stop the procedure” he pleaded in vain, “if I leave now I can be there in 15 hours”.

And then the big moment arrived – Shane Warne, cricket legend, taker of over 700 Test wickets, deliverer of the “Ball of the Century”, and one of only five of Wisden’s Cricketers of the 20th Century, walked over to the star-struck urology legend and shook hands.

They chatted for about 10 minutes about various great cricketing moments and about mutual friends in Indian cricket. They both seemed to be thoroughly enjoying themselves and one could tell that Indy was relishing every moment he was spending in the company of true cricket royalty. Shane then happily signed an Australian cricket jersey before we finally dragged Indy back to the Symposium upstairs. I don’t think it is unreasonable to say that he was somewhat starstruck:

  

The moment was shared by Daniel Moon on Twitter using the official meeting hashtag #bkcs14:

Social media metrics supplied by Symplur at that time showed healthy activity for a sub-specialist uro-oncology meeting with about 250 delegates:

However, when Shane Warne re-tweeted us to his 1.46 million followers, the meeting statistics went through the roof! We had gone from 37,000 digital impressions to almost 1,500,000 impressions:

In the twisted world of social media statistics, #bkcs14 has become one of the biggest scientific meetings in the world this year!

Indy then returned to the relatively mundane world he normally inhabits by showing footage of a robotic-assisted partial nephrectomy with zero ischaemia for a 10cm interpolar tumour in a solitary kidney (including vascular reconstruction of a feeding vessel), followed by a super-human robotic resection of a kidney tumour with level II caval thrombus done as part of a live surgery broadcast to 1000 people. Interesting for sure, but not what gets him really excited.

Declan Murphy
Urologist and Associate Editor (Social Media), BJUI
Melbourne, Australia
Twitter: @declangmurphy

 

Intra-operative pulmonary embolism secondary to dislodged tumor thrombus from synovial sarcoma of the kidney

Primary synovial sarcoma (PSS) of the kidney is a rare occurrence, with preoperative diagnosis difficult to distinguish from other renal neoplasms. Presented here is the case of a patient who underwent elective left laparoscopic nephrectomy for a 6-cm renal mass. Intra-operatively, she decompensated into PEA from multiple pulmonary emboli secondary to dislodged tumor thrombus requiring emergent sternotomy and embolectomy after placing the patient on cardiopulmonary bypass. Patient survived the surgery and has been placed on adriamycin, ifosfomide, mesna (AIM) chemotherapy. However, no definitive treatment of renal synovial sarcoma exists and prognosis is bleak despite primary surgical resection, chemotherapy, or radiotherapy.

Authors: Zhao, Philip;  Mikkilineni, Nina; Johnson, Kelly; Ankem, Murali
Corresponding Author: Philip Zhao MD, Division of Urology, Department of Surgery, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA. Email: [email protected]

 


Abstract

Primary synovial sarcoma (PSS) of the kidney is a rare occurrence, with preoperative diagnosis difficult to distinguish from other renal neoplasms. Presented here is the case of a patient who underwent elective left laparoscopic nephrectomy for a 6-cm renal mass. Intra-operatively, she decompensated into PEA from multiple pulmonary emboli secondary to dislodged tumor thrombus requiring emergent sternotomy and embolectomy after placing the patient on cardiopulmonary bypass. Patient survived the surgery and has been placed on adriamycin, ifosfomide, mesna (AIM) chemotherapy. However, no definitive treatment of renal synovial sarcoma exists and prognosis is bleak despite primary surgical resection, chemotherapy, or radiotherapy.

Introduction

Synovial sarcoma of the kidney was reported first by Faria et al. and Argani et al. in the beginning of the twenty-first century as a distinct subset of the embryonal sarcoma of the kidney [1,2]. Although synovial tumors occur primarily in the para-articular joints of extremities, they have been encountered in the lungs, mediastinum, heart, pharynx/larynx, kidneys, and other organs. Primary renal synovial sarcoma is extremely rare, with less than thirty-five cases reported in the literature [3, 4]. Its diagnosis cannot be based on imaging studies alone – it looks similar to other renal neoplasms on CT or MRI scans, but must be confirmed by molecular and cytogenetic analysis demonstrating the chromosomal translocation of t(X;18)(p11;q11) [2]. The disease is clinically aggressive and because of the paucity of cases, there are no optimal treatment plans except complete resection and a combination of adjuvant chemotherapy or radiotherapy [5]. We present a case of PSS of the kidney that, during nephrectomy, embolized the pulmonary arterial system, causing catastrophic decompensation, requiring the patient to undergo cardiopulmonary bypass with emergency embolectomy.

Case Report

A 44-year-old female initially presented in March 2011 with gross haematuria and left flank pain, and workup revealed a heterogeneous 6 x 5 cm left upper pole renal mass. A metastatic evaluation was negative. The patient had no prior medical or surgical history and was a non-smoker. Anxious with her diagnosis, she elected to have an elective laparoscopic nephrectomy performed at the earliest available time. An abdominopelvic CT scan with IV contrast (Figure 1) done two weeks prior to date of surgery showed the tumor without any extensive invasion outside of the kidney and with only an element of left renal vein involvement, that id extend into the vena cava. In fact, the edge of the tumor thrombus was about 1.5 cm from the IVC.
The patient underwent a left laparoscopic radical nephrectomy in April 2011 in the standard manner. After placing the patient in the right lateral decubitus position and creating the pneumoperitoneum, surgery proceeded uneventfully until dissection of the renal hilum. The left renal artery was identified and stapled without difficulty. The left gonadal, adrenal, and lumbar veins were all identified and ligated. The left renal vein was then dissected and a vascular stapler was slowly closed flush to the IVC and then pushed laterally towards the kidney before closing completely and firing. Immediately after firing the vascular stapler, the patient became bradycardic, hypotensive, and hypoxic, eventually leading to PEA. A catastrophic event was suspected and the surgery immediately ceased with deflation of the pneumoperitoneum, removal of all laparoscopic ports, and placement of the patient in the supine position. Although a tension pneumothorax was initially suspected, TEE confirmed significant right ventricular (RV) distension and signs of pulmonary embolism. Aggressive cardiopulmonary resuscitation began and cardiothoracic surgery was emergently consulted for cardiopulmonary bypass and embolectomy.
A femoral-femoral bypass was established and a standard sternotomy was performed with the pericardium opened. The RV was significantly dilated and there was high pulmonary arterial pressure by palpation. The right atrium (RA) and ascending aorta were both cannulated and the femoral lines were switched to the aortic arterial line and venous outflow from the RA to reestablish bypass. The patient was then systemically cooled to approximately 31 degrees Celsius. The pulmonary artery was then opened in a longitudinal direction and multiple clots as well as tumor thrombi were then removed from all the pulmonary arterial segmental branches on both the left and right sides (Figure 2). A frozen section sent off revealed spindle cell tumor. After all clots and tumors had been removed, the pulmonary artery was closed along with the chest, while keeping a chest tube in place. The nephrectomy was completed by making a left subcostal incision and removing the entire left kidney. A JP drain was left in place and the abdomen was then closed.
The patient remained intubated in the ICU and was weaned off the ventilator on post-operative day three. The rest of her hospitalization was complicated by acute renal failure, from which she was able to recover. Upper extremity DVT also developed, for which she was placed on therapeutic enoxaparin. The patient was ultimately discharged from the hospital to begin outpatient chemotherapy with adriamycin, ifosfomide, mesna (AIM). Pathological confirmation of primary monophasic synovial sarcoma of the kidney was obtained, with molecular studies detecting SYT-SSX2 fusion transcripts consistent with t(X,18) translocation. Although the fascial margins of the tumor were negative, there was extensive lymphovascular invasion and extension into the renal sinus. Final pathology of the pulmonary thrombi demonstrated metastatic synovial sarcoma.
A PET scan done a month after patient’s operation revealed extensive areas of hypermetabolic nodules and soft tissue densities in the left renal bed and significant lymphadenopathy in the retroperitoneum coursing down the left ureter consistent with metastatic spread of the cancer. A repeat CT scan of the chest also revealed a non-occlusive filing defect at the bifurcation of the right main pulmonary artery suggesting in situ thrombus, as well as new lytic osseous lesions in the intervertebral bodies suspicious for osseous metastases.

Discussion

Primary synovial sarcoma of the kidney is rare and tumors presenting with IVC thrombus are fewer still-there are only four cases reported in the literature [4]. Our case is the first report of a PSS thrombus dislodging and embolizing the pulmonary arterial tree, causing immediate decompensation and requiring emergency sternotomy and embolectomy after placing the patient on cardiopulmonary bypass. The case is especially interesting and highlights the aggressiveness of this tumor variant because only two weeks prior to surgery, a CT scan showed a grossly patent IVC with minimal tumor invasion of the left renal vein. There was a wide discrepancy between the amount of tumor burden removed from the pulmonary arteries and the small tumor thrombus in the renal vein identified on CT scan. A case may have been made for additional imaging (MRI) to better define the level of tumor thrombus. However, recent literature shows that CT and MRI both detect and assess caval thrombus with similar sensitivity and specificity –78% and 72%, 88% and 76%, respectively [6]. In retrospect, we could have used an intra-operative ultrasound to better delineate the exact edge of the tumor thrombus in the renal vein prior to ligation. We did not because of the grossly patent IVC on recent imaging and because the attending surgeon felt confident in his technique of closing the stapler partway and then “milking” any thrombus away from the IVC before firing.
There is no preoperative method to diagnose PSS without tissue samples for analysis. Differential diagnosis includes adult Wilms tumor, renal cell carcinomas, mesoblastic nephromas, primitive neuroectodermal tumors, primary renal rhabdosarcomas, and transitional cell carcinomas. Using reverse transcriptase polymerase chain reaction (RT-PCR), Argani et al. were able to identify the presence of SYT-SSX gene fusion from t(X; 18) [2]. Although five different variants of the SSX gene have been identified, only SSX1 and SSX2 have been shown to fuse with the SYT gene to create the biphasic and monophasic forms of PSS, respectively. Biphasic PSS contains both glandular and spindle epithelial elements while the monophasic form is only composed of spindle cells [4, 7]. The only consistent immunoreactive marker for PSS is vimentin, which was markedly positive in our patient’s tumor.
Although surgery is the mainstay of therapy, it is not enough alone to augment the already poor prognosis associated with renal PSS. Although there have been limited success with stereotactic body radiotherapy and ifosamide and doxorubicin-based chemotherapy with case reports showing complete remission after post-nephrectomy metastasis to the lung, most patients do not live beyond two years [8, 9, 10].

070fig1

 

 

 

 

 

 

 

Fig. 1

070fig2

 

 

 

 

 

 

Fig. 2

References

1. Faria P, Argani P, Epstein J. Primary synovial sarcoma of the kidney: A molecular subset of so called embryonal renal sarcoma. Mod Pathol Am. 1999;12:94.
2. Argani P, Faria PA, Epstein JI, Reuter VE, Perlman EJ, Beckwith JB, Ladanyi M. Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol. 2000 Aug;24(8):1087-96.
3. Gabilondo F, Rodríguez F, Mohar A, Nuovo GJ, Domínguez-Malagón H. Primary synovial sarcoma of the kidney: corroboration with in situ polymerase chain reaction. Ann Diagn Pathol. 2008;12:134-7.
4. Dassi V, Das K, Singh BP, Swain SK. Primary synovial sarcoma of kidney: A rare tumor with an atypical presentation. Indian J Urol. 2009 Apr-Jun;25(2): 269-271.
5. Kataria T, Janardhan N, Abhishek A, Sharan GK, Mitra S. Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature. J Cancer Res Ther. 2010 Jan-Mar;6(1):75-9.
6. Hallscheidt PJ, Fink C, Haferkamp A, Bock M, Luburic A, Zuna I, Noeldge G, Kauffmann G. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: prospective study with histopathological correlation. J Comput Assist Tomogr. 2005 Jan-Feb;29(1):64-8.
7. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlen M, et al. A novel fusion gene, SYT-SSX4: In synovial sarcoma. J Natl Cancer Inst. 1999;91:974-5.
8. Kataria T, Janardhan N, Abhishek A, Sharan GK, Mitra S. Pulmonary metastasis from renal synovial sarcoma treated by stereotactic body radiotherapy: a case report and review of the literature. J Cancer Res Ther. 2010 Jan-Mar;6(1):75-9.
9. Park SJ, Kim HK, Kim CK, Park SK, Go ES, Kim ME, et al. A case of renal synovial sarcoma: Complete remission was induced by chemotherapy with Doxorubicin and Ifosamide. Korean J Intern Med. 2004;19:62-5.
10. Long JA, Dinia EM, Saada-Sebag G, Cyprien J, Pasquier D, Thuillier C, Terrier N, Boillot B, Descotes JL, Rambeaud JJ. Primitive renal synovial sarcoma: a cystic tumor in young patients. Prog Urol. 2009 Jul;19(7):474-8.

 

Date added to bjui.org: 26/11/2012

DOI: 10.1002/BJUIw-2012-070-web

 

© 2024 BJU International. All Rights Reserved.